Clinical Trials Directory

Trials / Completed

CompletedNCT06745492

Low-dose Neostigmine at TOF Ratio of 0.7 Improves Neuromuscular Recovery

Low-dose Neostigmine at TOF Ratio of 0.7 Accelerates Neuromuscular Recovery Without Adverse Effects: a Prospective Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
59 (actual)
Sponsor
Seoul National University Hospital · Academic / Other
Sex
All
Age
20 Years
Healthy volunteers
Not accepted

Summary

This study is a prospective observational study. A total of 54 patients were included in this study. We observed the time from neostigmine administration to TOF ratio of 1.0.

Conditions

Interventions

TypeNameDescription
DRUGNeostigmine + Glycopyrrolatea 20 mcg/kg of neostigmine and 4 mcg/kg of glycopyrrolate were administered at a TOF ratio of 0.7.

Timeline

Start date
2022-10-01
Primary completion
2023-08-20
Completion
2023-08-25
First posted
2024-12-20
Last updated
2024-12-20

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT06745492. Inclusion in this directory is not an endorsement.